Ribometrix Raises $7.5M In Seed Funding to Advance Platform for Discovering and Developing Small Molecule Modulators of RNA to Treat Human Diseases. Brennan CaruthersOctober 31, 2017
Merck to Acquire Rigontec, RIG-I Therapeutics Pioneer, Advancing Leadership in Immuno-Oncology. Brennan CaruthersSeptember 6, 2017
F-star Expands its Relationship with Merck through a new Strategic Collaboration to Develop Bispecific Antibodies in Immuno-Oncology. Brennan CaruthersJune 4, 2017
Rigontec Starts First-In-Human, Phase I/II Trial of RIG-I Agonist RGT100 and Appoints Eugen Leo as Chief Medical Officer. Brennan CaruthersMay 3, 2017
Forge Therapeutics Raises $15M Series A Financing to Develop First Novel Gram-Negative Antibiotic In Decades. Brennan CaruthersApril 25, 2017
miRagen Therapeutics Completes Merger with Signal Genetics and Concurrent $40.7 Million Equity Financing. Brennan CaruthersFebruary 13, 2017
miRagen Therapeutics Announces Presentation of MRG-106 Clinical Data at American Society of Hematology Annual Meeting. Brennan CaruthersNovember 3, 2016
miRagen Therapeutics Appoints Kevin Koch, Ph.D., to Its Board of Directors. Brennan CaruthersSeptember 9, 2016
F‐star Announces Collaborative Agreement with Denali Therapeutics for the Development of a Multispecific Antibody Platform to Deliver Therapeutics Across the Blood‐Brain Barrier. Brennan CaruthersAugust 25, 2016
miRagen Therapeutics Initiates First Clinical Trial for MRG-106 in Lymphoma Patients. Brennan CaruthersMarch 2, 2016
Thrasos Announces Promising Results for Phase 2 THR-184 Dose Ranging Clinical Study for the Prevention of Acute Kidney Injury (AKI). Brennan CaruthersFebruary 29, 2016
F-star Enters into Collaborative Discovery & Development Agreement with AbbVie for Bispecific Antibodies in Immuno-oncology. Brennan CaruthersJanuary 11, 2016
miRagen Therapeutics Secures $41 million Series C Financing to Advance Two MicroRNA Programs into Clinical Trials. Brennan CaruthersNovember 10, 2015
Thrasos Completes Enrollment of Phase 2 THR-184 Clinical Studay for Acute Kidney Injury. Brennan CaruthersJuly 7, 2015
Thrasos Secures $21 Million to Complete Phase 2 Study of THR-184 in the Prevention of Acute Kidney Injury and Expand the Company's Renal Portfolio. Brennan CaruthersMarch 31, 2015
F-star Announces the Formation of Second Asset-Centric Vehicle, F-star Beta Ltd. Brennan CaruthersNovember 4, 2014
Bristol-Myers Squibb Enters into Agreement that Provides an Exclusive Option to Acquire F-star Alpha Ltd. and its Novel HER2-Targeted Therapy. Brennan CaruthersOctober 28, 2014
Thrasos Announces Successful Formal Interim Analysis and Clinical Update. Brennan CaruthersSeptember 16, 2014